FDA Warning: Yeast Infection Drug May Increase Risk of Miscarriage

April 28, 2016



On Tuesday, April 26th, the FDA announced that oral fluconazole (Diflucan) may contribute to increased risk of miscarriage when taken during pregnancy.  In its announcement, the Agency stated that it is evaluating the results of a Danish study suggesting that there could be a link between miscarriages and the product’s use.  “We are also reviewing additional data and will communicate our final conclusions and recommendations when our review is complete,” said the FDA.

What is fluconazole?

Fluconazole, sold under the brand name Diflucan and also as generics, is used to treat “yeast infections of the vaginal area, mouth, and esophagus.”  In addition, the medication can also be used to treat a fungal infection of the brain and spinal cord called cryptococcal meningitis that most often affects people with weakened immune systems, and used to prevent yeast infections that can spread to the rest of the body in cancer patients who have a weakened immune system.” The product works by killing the fungus or yeast as well as preventing further growth.  Fluconazole is available in powder (for suspension), capsule, and tablet form and can be obtained only with a prescription.

FDA Warning

FDA says that health care professionals should be aware of the Center for Disease Control and Prevention’s (CDC’s) guidelines that advise pregnant women to use only topical antifungal products to treat vulvovaginal yeast infections, “including for longer periods than usual if these infections persist or reoccur.”

FDA also advises patients who are either pregnant or trying to become pregnant to talk to their doctor about alternative treatment options for yeast infections.

“Until FDA’s review is complete and more is understood about this study and other available data, FDA advises cautious prescribing of oral fluconazole in pregnancy,” said the Agency in its recent warning about the medication.

Medical Devices Agency Alerts

February 28, 2019

Draft Guidance: Requesting Nonbinding Feedback After an FDA Inspection of Your Medical Device Establishment

On Tuesday, February 19th, FDA published a draft guidance for medical device makers which identifies a process for companies to request nonbinding feedback on certain FDA Form 483 deficiencies noted...

Read the Full Article
Agency Alerts General Regulatory

August 28, 2015

FDA Extends Comment Period For Its “Request for Quality Metrics” Draft Guidance

Last month, FDA published a draft guidance titled “Request for Quality Metrics,” which outlined the ways in which it intends to collect and use quality metrics. The guidance states that the data will...

Read the Full Article
Medical Devices Agency Alerts

November 30, 2018

FDA Announces Plans to Modernize its 510(k) Medical Device Approval Process

On Monday, November 26th, FDA announced changes to modernize the 510(k) clearance pathway, which is the most common medical device submission and allows for the allows for the “clearance of low- to...

Read the Full Article